← Eichor
Study identifier: NCT06789757 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma  ·  Sponsor: Inova Health Care Services

PhasePhase 2
Planned participants19
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Keary Jane't  ·  571-472-4724  ·  keary.janet@inova.org

Elahe Mollapour  ·  571-472-4724  ·  elahe.mollapour@inova.org

Always discuss trial participation with your own doctor first.

Locations (2)

Inova Schar Cancer Institute - Fair OaksFairfax, Virginia, United StatesRecruiting
Inova Health Care ServiceFalls Church, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06789757